ArticleJournal of orthopaedic translation2026
Silencing SFRP1 in bone mesenchymal stem cells alleviates pediatric B-ALL-driven bone loss by activating Wnt/β-catenin signaling.
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating mechanistic research and emerging technologies to advance clinical translation in orthopaedics.Journal of orthopaedic translation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bone loss is the most common skeletal complication of childhood acute lymphoblastic leukemia (ALL) and seriously affects the long-term survival quality of children. However, the mechanisms behind bone loss are complicated and need to be elucidated. This study seeks to examine the principal parameters influencing the osteogenic development of bone marrow mesenchymal stem cells (BMSCs) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) experiencing bone loss, and to identify viable ways for alleviating bone loss. Methods: Firstly, bone mass of adolescent B-ALL patients and mice were evaluated with aged-matched cohorts. Then, human BMSCs (hBMSCs) were isolated from pediatric B-ALL patients and characterized by Flow Cytometry Assay (FCA). ALP, ARS, Oil Red O and toluidine blue staining were used to evaluate the trilineage differentiation of hBMSCs. Integrated RNA-seq and proteomic analyses were employed to identify differentially target osteogenic regulators in B-ALL-derived hBMSCs. On the based that secreted frizzled-related protein 1 (SFRP1) was demonstrated to be a regulator on B-ALL BMSC osteogenesis, BMSC-targeted liposomal nanocarriers were engineered to encapsulate lentiviral particles carrying therapeutic shSFRP1 RNA and grafted with E7 peptide (shSFRP1@Lipo-E7), enabling cell-specific gene silencing in BMSCs. Subsequently, shSFRP1@Lipo-E7 was delivered into B-ALL mice by tail vein injection and bone quality were evaluated by mico-CT and histomorphometric analysis. Results: Adolescent B-ALL patients exhibited significant vertebral bone loss, with 33.8% of patients affected. In B-ALL mice, BMD and newbone formation were markedly reduced, while osteoclast activity increased. An increased expression of SFRP1 was identified to impair osteogenesis of BMSCs from B-ALL patients. Consequently, a BMSC-targeted nanoplatform, E7 peptide-modified liposomes containing lentiviral shSFRP1 (shSFRP1@Lipo-E7) was constructed successfully. As anticipated, shSFRP1@Lipo-E7 effectively suppressed SFRP1 expression in trabecular osteoblasts and rescued B-ALL mice from bone loss, supported by significantly increasing BMD and improved trabecular structure. Both Conclusion: High SFRP1 expression in B-ALL BMSCs suppresses osteogenesis and contributes to bone loss in B-ALL cohorts by inhibiting Wnt/β-catenin signaling, which afford a potential translatable target to reprogram bone homeostasis and prevent bone fragility in ALL patients. The Translational Potential of this Article: Given the negative correlation between SFRP1 overexpression in BMSCs of pediatric B-ALL related bone mass loss, precisely targeting SFRP1 in MSCs for intervention holds promise as a therapeutic strategy to rescue bone loss in this disease category.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.